Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25696320 | 0.91 | KDM4E (0.33) | CYP2D6KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL20148100 | 0.87 | KDM4E (0.31) | CYP2D6KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL25821404 | 0.85 | TSHR (0.32) | CYP2D6KDM4ESMN1; SMN2 | |
| SCHEMBL12396796 | 0.84 | KDM4E (0.39) | CYP2D6KDM4EHRH3 | |
| SCHEMBL10111445 | 0.83 | CYP2D6 (0.46) | CYP2D6KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL19083175 | 0.83 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL21216987 | 0.82 | USP2 (0.45) | CYP2D6SMN1; SMN2 | |
| SCHEMBL7770721 | 0.81 | CYP2D6 (0.45) | CYP2D6KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL24607211 | 0.80 | CYP2D6 (0.53) | CYP2D6SMN1; SMN2 | |
| SCHEMBL24941850 | 0.79 | CYP2D6 (0.35) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | CYP2D6 4679/4885KDM4E 2222/4885SMN1; SMN2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.